Hot or Not, Stock Market Edition: 11/11/2025

Happy Veteran’s Day! The market’s open, and here are some of the stocks we’re following RN:

• HOT: Bristol Myers Squibb (BMY) just got upgraded to a Strong Buy; Jazz Pharmaceuticals (JAZZ) crushes earnings expectations
• NOT: Martin Marietta Materials (MLM) feels the industry squeeze; CAVA Group (CAVA) is in free-fall after downgrading expectations

P.S. For more stocks making moves, check out our Zen Ratings Upgrades & Downgrades screener.

A note from our sponsors...

🔥 HOT: Pharma giant Bristol Myers Squibb (BMY) is firing on all cylinders. Not only is it the #1-rated stock in an A-rated industry (General Drug Manufacturers), but it currently ranks in the 99th percentile of the 4600+ stocks we track based on a 115-factor review of traditional and innovative fundamental checks. Its recent Zen Rating upgrade to A (Strong Buy) is warranted — the Component Grades reveal great strength in key areas like Value (A rating) and Growth (B rating) that speak to both stability and expansion potential. Lower interest rates would further boost the appeal of BMY's dividend yield, making it a magnet for income-focused investors seeking quality. The bottom line? BMY's combination of fortress balance sheet, industry leadership, and exposure to secular growth trends makes it a core holding for risk-averse growth seekers.

🥶 NOT: Woof! Building material stocks have been struggling lately (Industry grade: D), and Martin Marietta Materials (MLM) is no exception. The stock just got downgraded in our Zen Ratings system to the lowest possible grade — an F, or Strong Sell. The core problem is margin compression. While MLM reported record Q3 results and raised guidance, net profit margins have declined significantly, and earnings and revenue both missed estimates by roughly 10%. This is the classic trap: top-line growth masking deteriorating profitability. Digging into the Component Grades, you’ll find a Growth rating of F that signals structural challenges ahead — and with a Value rating of D and a Financials rating of C, the company's valuation no longer reflects its slowing earnings trajectory. The bottom line? MLM's margin pressure, valuation disconnect, and industry headwinds outweigh the near-term earnings beat. Better opportunities exist elsewhere.

🔥 HOT: Biotech heavyweight Jazz Pharmaceuticals (JAZZ) just delivered a masterclass in beating expectations, with Q3 earnings crushing estimates by over 41% and revenue surging on the back of new drug launches and portfolio expansion. The real story here is execution. Jazz reported record revenue driven by strategic FDA approvals and a neuroscience portfolio firing on all cylinders. JAZZ has momentum on its side, backed by a stellar Zen Rating of A — it actually ranks in the 99th percentile of stocks we track, with exceptional fundamentals across the board. The Component Grades reveal an outstanding Value rating of A and a solid Growth rating of B, demonstrating the company is delivering both profitability and expansion potential. Safety and Financials grades of B round out a balanced risk-reward profile. The bullish news flow around Q3 results and new drug launches suggests the market is just beginning to price in the company's momentum. Jazz has the ratings, the earnings beat, and the catalysts to justify continued potential upside. 

🥶 NOT: You don’t win friends with salad! Fast-casual dining darling CAVA Group (CAVA) appears to have hit a wall. The stock was just downgraded in our Zen Ratings system to an F (Strong Sell) following news that CAVA just slashed full-year guidance amid slowing same-store sales growth (which also led to a 9.5% single-day plunge). Why? Gen Z, CAVA's core demographic, is under severe financial pressure and pulling back on discretionary spending at fast-casual chains. Sadly, the Component Grades demonstrate the stock is broken on virtually every metric that matters. With Momentum AND Sentiment ratings of F, and a Value rating of D, there's simply no angle that works here. The rating downgrade to Strong Sell reflects the deteriorating outlook, and the technical picture is equally grim with the stock trading well below all major moving averages.

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.